United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Soleno Therapeutics as the specialty pharmacy ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

Third-party companies known as pharmacy benefit managers, which administer prescription drug benefits for health insurance ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ ... this pattern is very common. Simply said, the United States lacks the infrastructure to handle the ...

Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Equities research analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for Fate Therapeutics in a research note ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of ...

March 10 (Reuters) - India's Sun Pharmaceutical Industries (SUN.NS), opens new tab said on Monday it will acquire Checkpoint Therapeutics (CKPT.O), opens new tab, a U.S.-based immunotherapy and ...

Journavx has been placed on Tier 3 of Optum Rx Premium and Select Formularies and is being further evaluated by the Optum Rx National Pharmacy & Therapeutics Committee for clinical value and safety.

Axsome Therapeutics has entered into a settlement ... The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hikma of ...